Amir Anis
Hematology & Oncology · Joplin, MONPI 1598859084
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $598, 3.4 times the $177 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in MO, where the typical reported total is $1,571.
Across 61 payments — averaging $32.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$216
- Galvanize Therapeutics, Inc$156
- Caris MPI, Inc.$146
- Novartis$132
- Gilead$129
- AbbVie$127
- plus $1K from 19 others
Across 11 payments — averaging $2695.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$17K
- Daiichi Sankyo Inc.$13K
- Merck$96
What the payments were for
- Food & beverage$1,81293%
- Education$1427%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 14 | $216 |
| Galvanize Therapeutics, Inc | 1 | $156 |
| Caris MPI, Inc. | 1 | $146 |
| Novartis | 5 | $132 |
| Gilead(2 entities) | 4 | $129 |
| AbbVie | 4 | $127 |
| AstraZeneca | 5 | $104 |
| Lilly USA, LLC | 2 | $103 |
| Johnson & Johnson | 2 | $102 |
| Beigene USA, Inc. | 1 | $95 |
| E.r. Squibb & Sons, L.L.C. | 1 | $92 |
| Amgen | 3 | $89 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $81 |
| EMD Serono, Inc. | 2 | $65 |
| Bristol Myers Squibb | 3 | $52 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Puma Biotechnology, Inc. | 2 | $41 |
| Astellas Pharma US Inc | 1 | $32 |
| Array Biopharma Inc | 1 | $30 |
| Genentech USA, Inc. | 1 | $29 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Merck | 1 | $18 |
| Exelixis Inc. | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $17 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALIYA SYSTEM$156
- MI CANCER SEEK$146
How this compares
$1,954 in reported general payments places this provider in the 50th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 25 | $431,556 |
| PomalystPomalidomide | 13 | $279,394 |
| ScemblixAsciminib Hydrochloride | 12 | $217,568 |
| ImbruvicaIbrutinib | 11 | $120,381 |
| XareltoRivaroxaban | 41 | $33,390 |
| Ondansetron Hcl | 25 | $2,804 |
| Anastrozole | 148 | $1,483 |
| Fentanyl | 14 | $1,368 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 36 | $1,276 |
| Oxycodone Hcl | 52 | $851 |
| Levofloxacin | 13 | $827 |
| Tamoxifen Citrate | 42 | $789 |
| Dexamethasone | 28 | $640 |
| Acyclovir | 32 | $462 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 31 | $443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $52 | $431,55625 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $92 | $279,39413 claims |
| NovartisScemblix | $132 | $217,56812 claims |
| Johnson & JohnsonXarelto | $102 | $33,39041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Joplin
- Anisa HassanJoplin$9K
- Matthew MillerJoplin$8K
- Regine LeconteJoplin$5K
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.